West Pharmaceutical Services Cash Flow from Investing Activities 2010-2024 | WST

West Pharmaceutical Services annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • West Pharmaceutical Services cash flow from investing activities for the quarter ending March 31, 2024 was $-0.091B, a 10.35% increase year-over-year.
  • West Pharmaceutical Services cash flow from investing activities for the twelve months ending March 31, 2024 was $-0.883B, a 26.56% increase year-over-year.
  • West Pharmaceutical Services annual cash flow from investing activities for 2023 was $-0.369B, a 27.93% increase from 2022.
  • West Pharmaceutical Services annual cash flow from investing activities for 2022 was $-0.288B, a 13.87% increase from 2021.
  • West Pharmaceutical Services annual cash flow from investing activities for 2021 was $-0.253B, a 41% increase from 2020.
West Pharmaceutical Services Annual Cash Flow Investing
(Millions of US $)
2023 $-369
2022 $-288
2021 $-253
2020 $-180
2019 $-228
2018 $-101
2017 $-134
2016 $-176
2015 $-130
2014 $-104
2013 $-150
2012 $-116
2011 $-121
2010 $-74
2009 $-122
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $24.141B $2.950B
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments: Proprietary Products and Contract-Manufactured Products.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $74.038B 20.77
Becton Dickinson (BDX) United States $67.041B 18.97
Cardinal Health (CAH) United States $24.179B 13.83
Align Technology (ALGN) United States $19.363B 37.38
Cooper (COO) United States $18.745B 27.70
Labcorp (LH) United States $16.431B 14.14
Henry Schein (HSIC) United States $8.879B 15.80
DENTSPLY SIRONA (XRAY) United States $5.816B 15.06
Merit Medical Systems (MMSI) United States $4.715B 25.84
CONMED (CNMD) United States $2.354B 21.35
Patterson (PDCO) United States $2.203B 10.55
STAAR Surgical (STAA) United States $2.040B 78.36
Atrion (ATRI) United States $0.810B 43.26
Lifevantage (LFVN) United States $0.097B 12.48
Pro-Dex (PDEX) United States $0.067B 33.98
Biolase (BIOL) United States $0.006B 0.00